In vivo imaging of neurotransmission and brain receptors in dementia

Journal of Neuroimaging

Volumn 18, Issue 2, 2008, Pages 111-124

  Pappatà, Sabina ^a,b   Salvatore, Elena ^a   Postiglione, Alfredo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

Dementia; Neurochemical imaging; Neurotransmission; PET; SPECT

Indexed keywords

BRAIN RECEPTOR; NEUROTRANSMITTER;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; HUMAN; IN VIVO STUDY; NEUROCHEMISTRY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROTRANSMITTER AGENTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 41549129489     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2007.00194.x     Document Type: Review

References (111)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976 2 (8000 1403.
2. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999 66 (2 137 147.
3. Volkow ND, Rosen B, Farde L. Imaging the living human brain: magnetic resonance imaging and positron emission tomography. Proc Natl Acad Sci USA 1997 94 (7 2787 2788.
4. Minoshima S, Frey KA, Cross DJ, Kuhl DE. Neurochemical imaging of dementias. Semin Nucl Med 2004 34 (1 70 82.
5. Elsinga PH. Radiopharmaceutical chemistry for positron emission tomography. Methods 2002 27 : 208 217.
6. Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 2001 28 : 595 608.
7. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000 20 (3 423 451.
8. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992 4 (4 303 328.
9. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, Alfano B, Brunetti A, Baron JC, Salvatore M. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 2004 45 (2 192 201.
10. Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev 1997 23 (1-2 28 46.
11. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999 22 (6 273 280.
12. Bentley P, Husain M, Dolan RJ. Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory. Neuron 2004 41 (6 969 982.
13. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer's disease. In : Alzheimer's Disease. Terry RD, Katzman R, Bick KL, eds, New York : Raven Press, 1994 263 291.
14. Ruberg M, Rieger F, Villageois A, Bonnet AM, Agid Y. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res 1986 362 (1 83 91.
15. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith IG, Perry RH. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994 5 (7 747 749.
16. Warren NM, Piggott MA, Perry EK, Burn DJ. Cholinergic systems in progressive supranuclear palsy. Brain 2005 128 (Pt 2 239 249.
17. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 2003 60 (7 1183 1185.
18. Kuhl DE, Koeppe RA, Fessler JA, Minoshima S, Ackermann RJ, Carey JE, Gildersleeve DL, Frey KA, Wieland DM. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 1994 35 (3 405 410.
19. Shinotoh H, Fukushi K, Nagatsuka S, Irie T. Acetylcholinesterase imaging: its use in therapy evaluation and drug design. Curr Pharm Des 2004 10 (13 1505 1517.
20. Atack JR, Perry EK, Bonham JR, Boakes R, Candy JM. Loss and recovery of acetylcholinesterase molecular forms in the fornix-lesioned rat hippocampus. Neurosci Lett 1987 79 (1-2 179 184.
21. Fowler JS, Ding YS, Volkow ND. Radiotracers for positron emission tomography imaging. Semin Nucl Med 2003 33 (1 14 27.
22. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996 40 (3 399 410.
23. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997 349 (9068 1805 1809.
24. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999 52 (4 691 699.
25. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000 48 (2 194 200.
26. Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B, Kalbe E, Heiss WD. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 2004 21 (1 136 143.
27. Rinne JO, Kaasinen V, Jarvenpaa T, Nagren K, Roivainen A, Yu M, Oikonen V, Kurki T. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003 74 (1 113 115.
28. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003 60 (12 1745 1748.
29. Eggers C, Herholz K, Kalbe E, Heiss WD. Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. Neurosci Lett 2006 408 (1 46 50.
30. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci 1995 92 (26 12260 12264.
31. Herholz K, Weisenbach S, Kalbe E, Diederich NJ, Heiss WD. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 2005 16 (13 1431 1434.
32. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Constantine G, Mathis CA, Moore RY, DeKosky ST. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 2005 380 (1-2 127 132.
33. Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm Suppl 1996 47 : 73 101.
34. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999 281 (15 1401 1406.
35. Hu L, Wong TP, Cote SL, Bell KF, Cuello AC. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic pre-synaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience 2003 121 (2 421 432.
36. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000 48 (3 391 395.
37. Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T, Tanada S, Irie T. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001 56 (3 408 410.
38. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, Meltzer CC, Constantine G, Davis JG, Mathis CA, Dekosky ST, Moore RY. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005 76 (3 315 319.
39. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry 2001 49 (3 211 220.
40. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995 64 (4 1888 1891.
41. Kendziorra K, Meyer P, Wolf H, Barthel H, Hesse S, Seese A, Sorger D, Patt M, Becker G, Schildan A, Gertz HJ, Sabri O. Cerebral nicotinic acetylcholine receptors in patients with Alzheimer's disease assessed with 2-[18F]F-A85380 PET-correlations to dementia severity. Neuroimage Suppl 2 2006 31 : T39.
42. O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 2007 78 (4 356 362.
43. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, Perry RH, Perry EK, Wyper D. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 2004 29 (1 108 116.
44. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005 65 (11 1716 1722.
45. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis ChA, Davis JG, Moore RY, Dekosky ST. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006 253 (2 242 247.
46. Herholz K. PET studies in dementia. Ann Nucl Med 2003 17 (2 79 89.
47. Hirano S, Shinotoh H, Kobayashi T, Tsuboi Y, Wszolek ZK, Aotsuka A, Tanaka N, Ota T, Fukushi K, Tanada S, Irie T. Brain acetylcholinesterase activity in FTDP-17 studied by PET. Neurology 2006 66 (8 1276 1277.
48. Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999 46 (1 62 69.
49. Pappata S, Traykov L, Tavitian B, Damier P, Dubois B, Jobert A, Crouzel C, Di Giamberardino L. Striatal reduction of acetylcholinesterase (AChE) in patients with progressive supranuclear palsy (PSP) as measured by PET and 11C-physostigmine (11C-PHY). J Cereb Blood Flow and Metab 1997 Suppl 1 17 : S687.
50. Pappata S, Tavitian B, Traykov L, Jobert A, Dalger A, Mangin JF, Crouzel C, DiGiamberardino L. In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 1996 67 (2 876 879.
51. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003 2 (4 229 237.
52. Farr SA, Flood JF, Morley JE. The effect of cholinergic, GABAergic, serotonergic, and glutamatergic receptor modulation on post-trial memory processing in the hippocampus. Neurobiol Learn Mem 2000 73 (2 150 167.
53. Maubach K. GABA(A) receptor subtype selective cognition enhancers. Curr Drug Targets CNS Neurol Disord 2003 2 (4 233 239.
54. Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behaviorial and psychological symptoms of dementia. Can J Psychiatry 2004 49 (7 439 453.
55. Beer HF, Bläuenstein PA, Hasler PH, Delaloye B, Riccabona G, Bangerl I, Hunkeler W, Bonetti EP, Pieri L, Richards JG, Schubiger PA. In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 1990 31 (6 1007 1014.
56. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol 1995 52 (3 314 317.
57. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, Toyama H, Oda K, Katayama Y. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999 13 (5 309 315.
58. Soricelli A, Postiglione A, Grivet-Fojaja MR, Mainenti PP, Discepolo A, Varrone A, Salvatore M, Lassen NA. Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses. Eur J Nucl Med 1996 23 (10 1323 1328.
59. Fukuchi K, Hashikawa K, Seike Y, Moriwaki H, Oku N, Ishida M, Fujita M, Uehara T, Tanabe H, Kusuoka H, Nishimura T. Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease. J Nucl Med 1997 38 (3 467 470.
60. Pappata S, Varrone A, Milan G, Sansone V, Iavarone A, Panico MR, Quarantelli M, Mollica C, De Falco C, Loré E, Postiglione A, Salvatore M. SPECT study of GABAA/BZD receptors and cerebral blood flow in mild cognitive impairment (MCI). Neuroimage Suppl. 2 2006 31 : T169.
61. Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, Gilman S. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 2000 54 (9 1768 1773.
62. Ihara M, Tomimoto H, Ishizu K, Mukai T, Yoshida H, Sawamoto N, Inoue M, Doi T, Hashikawa K, Konishi J, Shibasaki H, Fukuyama H. Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis: a positron emission tomography study. Stroke 2004 35 (4 942 947.
63. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Claudio Cuello A. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 2006 27 (11 1644 1657.
64. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O'Brien JT. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry 2004 161 (6 1096 1102.
65. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF 3rd. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998 18 (6 407 430.
66. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006 66 (1 17 22.
67. Blin J, Baron JC, Dubois B, Crouzel C, Fiorelli M, Attar-Levy D, Pillon B, Fournier D, Vidailhet M, Agid Y. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain 1993 116 (Pt 3 497 510.
68. Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, Mulsant BH, Ben-Eliezer D, Lopresti B, DeKosky ST, Reynolds CF 3rd. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 1999 156 (12 1871 1878.
69. Versijpt J, Van Laere KJ, Dumont F, Decoo D, Vandecapelle M, Santens P, Goethals I, Audenaert K, Slegers G, Dierckx RA, Korf J. Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiol Aging 2003 24 (4 553 561.
70. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, Waldemar G, Knudsen GM. Reduced 5-HT(2A) receptor binding in patients with mild cognitive impairment. Neurobiol Aging 2007 Jun 1 [Epub ahead of print]
71. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci 2006 103 (3 702 707.
72. Franceschi M, Anchisi D, Pelati O, Zuffi M, Matarrese M, Moresco RM, Fazio F, Perani D. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 2005 57 (2 216 225.
73. Robbins TW. Dopamine and cognition. Curr Opin Neurol 2003 16 (Suppl. 2 S1 S2.
74. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, Ballard C, Perry EK. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999 122 (Pt 8 1449 1468.
75. Pillon B, Czernecki V, Dubois B. Dopamine and cognitive function. Curr Opin Neurol 2003 16 (Suppl. 2 S17 S22.
76. Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 2006 59 (10 898 907.
77. Marie RM, Barre L, Dupuy B, Viader F, Defer G, Baron JC. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 1999 260 (2 77 80.
78. Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005 76 (9 1204 1210.
79. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000 57 (4 470 475.
80. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, Brooks DJ. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002 125 (Pt 6 1358 1365.
81. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, Aarsland D, McKeith IG. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004 61 (6 919 925.
82. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol 2004 3 (1 19 28.
83. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CL. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic pre-synaptic ligand. J Neurol Neurosurg Psychiatry 2002 73 (2 134 140.
84. Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, Shinkawa M, Itoh M, Ido T, Sasaki H. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000 55 (10 1575 1577.
85. Colloby SJ, O'Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, Williams ED. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004 23 (3 956 966.
86. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona CL. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004 62 (9 1568 1572.
87. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol 2004 55 (6 774 780.
88. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince P, Perry R, McKeith I, Katona CL. Dementia with lewy bodies: A comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry 2007 Mar 12 [Epub ahead of print].
89. McKeith I, O'brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C for the DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with (123)I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007 6 (4 305 313.
90. Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005 32 (10 1176 1185.
91. Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, Wernecke KD, Kupsch A, Felix R, Venz S. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005 112 (5 677 692.
92. Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL. Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997 24 (6 609 614.
93. Rinne JO, Sahlberg N, Ruottinen H, Nagren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 1998 50 (1 152 156.
94. Tyrrell PJ, Sawle GV, Ibanez V, Bloomfield PM, Leenders KL, Frackowiak RS, Rossor MN. Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type. Arch Neurol 1990 47 (12 1318 1323.
95. Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, Battistin L. Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology 1996 47 (4 1065 1068.
96. Kemppainen N, Ruottinen H, Nagren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 2000 55 (2 205 209.
97. Meguro K, Yamaguchi S, Itoh M, Fujiwara T, Yamadori A. Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: a double-tracer PET study. Neurology 1997 49 (4 941 945.
98. Tanaka Y, Meguro K, Yamaguchi S, Ishii H, Watanuki S, Funaki Y, Yamaguchi K, Yamadori A, Iwata R, Itoh M. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann Nucl Med 2003 17 (7 567 573.
99. Kemppainen N, Laine M, Laakso MP, Kaasinen V, Nagren K, Vahlberg T, Kurki T, Rinne JO. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 2003 18 (1 149 154.
100. Sperfeld AD, Collatz MB, Baier H, Palmbach M, Storch A, Schwarz J, Tatsch K, Reske S, Joosse M, Heutink P, Ludolph AC. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999 46 (5 708 715.
101. Pal PK, Wszolek ZK, Kishore A, de la Fuente-Fernandez R, Sossi V, Uitti RJ, Dobko T, Stoessl AJ. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). Parkinsonism Relat Disord 2001 7 (2 81 88.
102. Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002 58 (10 1489 1493.
103. Frisoni GB, Pizzolato G, Bianchetti A, Chierichetti F, Ferlin G, Battistin L, Trabucchi M. Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results. Acta Neurol Scand 1994 89 (3 199 203.
104. Baron JC, Maziere B, Loc'h C, Cambon H, Sgouropoulos P, Bonnet AM, Agid Y. Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 1986 6 (2 131 136.
105. Brooks DJ. PET studies in progressive supranuclear palsy. J Neural Transm Suppl 1994 42 : 119 134.
106. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, Pauli S, Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997 120 : 503 514.
107. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, Robbins TW, Sahakian BJ. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 1998 121 : 1343 1355.
108. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, Yamada M. Value of 123I-MIGB radioactivity in the differential diagnosis of DLB from AD. Neurology 2006 66 (12 1850 1854.
109. Pappata S, Dehaene S, Poline JB, Gregoire MC, Jobert A, Delforge J, Frouin V, Bottlaender M, Dolle F, Di Giamberardino L, Syrota A. In vivo detection of striatal dopamine release during reward: a PET study with [(11)C]raclopride and a single dynamic scan approach. Neuroimage 2002 16 (4 1015 1027.
110. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 2006 97 (6 1700 1725.
111. Cagnin A, Kassiou M, Meikle SR, Banati RB. In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol Scand Suppl 2006 185 : 107 114.